Proteomics can be used to distinguish different molecular subtypes of HER2-positive breast cancer in clinical practice and reveal differences in signal transduction pathways, protein expression, and potential therapeutic targets among these subtypes. The gene discussed is ERBB2; the disease is breast carcinoma.